Zenas BioPharma, Inc. (NASDAQ: ZBIO) is a compelling player in the biotechnology sector, with a focus on developing transformative immunology-based therapies. Headquartered in Waltham, Massachusetts, Zenas is making waves with its innovative pipeline, featuring lead product candidates like obexelimab, aimed at tackling complex immune and inflammatory diseases.

With a market capitalization of $1.41 billion, Zenas BioPharma is positioned as a promising contender within the healthcare industry. Currently, the stock is trading at $26.36, reflecting a marginal price change of 0.33 (0.01%). Over the past year, ZBIO has demonstrated significant volatility, with a 52-week range of $6.61 to $43.17, which underscores the dynamic nature of…